% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

  • vladimer_harkonnen vladimer_harkonnen Apr 5, 2007 12:27 PM Flag

    When is Ceplene news expected?

    Any info please.
    I'm thinking of taking a core position in this. I've been watching this for about 4 months and just can't pull the trigger. It should be at least double it's current price on sheer risk/adjusted baseline alone.

    I'm also long SIGA and looking to get back into MEMY after the summer.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • A guy named "kevin Schulls" (sp?) asked a great question during that oncology webcast...didn't you think so synergykjs? haha, really got to the heart of azixa and I really like the double digit percent of royalties on $1B drugs!!! (i smell hundreds of millions)


    • Myriad has stated that they want Azixa on the shelves in early 08.

      Happy Easter to all!!

    • picept market cap - $50million

      Epicept-Ceplene (1-2 billion sales - World wide)
      Border Recommendation from EMEA(EU) in april 2007, EMEA decision in Q3 2007
      Filing for a FDA approval later this year.

      October 9, 2006
      EpiCept Files for Marketing Approval of Ceplene(TM) in European Union

      Ceplene is EpiCept's lead oncology product that is administered with Interleukin-2 for first remission in Acute Myeloid Leukemia patients. Indication is a form of leukemia called AML. VERY strong phIII data in a big randomized study that met the prim endpoints and had high stat significance!
      They have already got the "day-120 list" from the agency with questions and a f"irst conclusion" under the central procedure anf they were very positive.

      CEO Jack Talley:
      The odds look good for approval as the European Agency had already designated Ceplene Orphan Drug Status, and phase 3 results had met critical endpoints.

      According to analysts in Sweden 80% chance of getting approved by EMEA, see link

      Next drug:
      Epicept-Azixa (2-3 billion - World wide)
      Cancer drug - primary and metastatic brain cancer
      There are approximately 170,000 new cases of metastatic brain tumors in the United States each year, and this number has risen steadily.Patients with glioblastoma multiforme (GBM) will be treated with Azixa, Azixa and oxaliplatinterm, or oxalplatin alone and compared for survival rates. The 5 year survival rate of GBM stands at <3% and has remained unchanged for over 30 years. One problem with present cancer drugs is they cannot pass the blood-brain barrier (BBB) in efficiently high doses to act on the cancer. The BBB is the layer of tightly packed endothelial cells surrounding the brain preventing high-molecular weight molecules from entering the brain. Here is a quick reference to a good definition of the blood-brain barrier.
      Azixa has been shown to cross the BBB and has two anti-tumor functions. It acts as a cytotoxin and a vascular disrupting agent. It inhibits microtubule formation in cells and in the new blood vessels being formed in the tumor to supply it with nutrients.Ongoing phase 2 trials,50-70 centers in both the United States and Europe.

      Fast track admission FDA- hit the market in 2008 (The 5 year survival rate of GBM stands at <3% and has remained unchanged for over 30 years)

0.2131-0.0109(-4.87%)Oct 21 3:59 PMEDT